<DOC>
	<DOCNO>NCT01050218</DOCNO>
	<brief_summary>The purpose study learn long-term treatment DVS SR safe treat pain symptom associate diabetic peripheral neuropathy .</brief_summary>
	<brief_title>Study Evaluating Long-Term Safety Desvenlafaxine Succinate Sustained-Release ( DVS SR ) Subjects With Pain Associated With Diabetic Peripheral Neuropathy</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Outpatients complete doubleblind treatment study 322 ( NCT01050218 ) DPN . Subjects must complete scheduled evaluation , major protocol violation event , opinion investigator , would preclude subject 's entry longterm openlabel study . Women childbearing potential must negative serum pregnancy test day 91 shortterm study . A woman childbearing potential one biologically capable become pregnant . `` Biologically capable '' include woman use contraceptive whose sexual partner either sterile use contraceptive . Sexually active woman participate study biologically capable become pregnant must use medically acceptable form contraception study least 15 day last dose test article . Medically acceptable form contraception include oral contraceptive , transdermal , injectable , implantable method , intrauterine device , properly use doublebarrier contraception , eg , condom plus diaphragm . Presence new and/or clinically important medical condition might compromise subject safety ( include , limited , significant change glycemic control ) . Pregnancy , lactation , plan become pregnant study . Use prohibit treatment . Meets exclusion criterion list study 322 ( NCT01050218 ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Diabetic Peripheral Neuropathy</keyword>
</DOC>